Unfit patients even have the alternative of venetoclax moreover obinutuzumab (VO) as frontline therapy. This relies on a period III demo that as opposed VO with ClbO in elderly/unfit patients.113 VO was excellent concerning reaction rate and progression-free of charge survival, and had a comparable protection profile. With this trial https://chiefg208cks5.wikitidings.com/user